Fed makes first interest-rate hike of 2023; Powell speaks at press conference

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Visitors trend2W10W9M

18.64

+0.38

(+2.08%)

As of 02:36PM EST. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Relative Strength Index (RSI)

View all chart patterns

Performance Outlook

Previous Close	18.26
Open	18.34
Bid	18.76 x 900
Ask	18.77 x 800
Day's Range	18.06 - 18.78
52 Week Range	10.81 - 21.25
Volume	258,760
Avg. Volume	752,373

Market Cap	772.015M
Beta (5Y Monthly)	1.17
PE Ratio (TTM)	N/A
EPS (TTM)	-2.20
Earnings Date	Feb 28, 2023 - Mar 06, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	22.50

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ICPT

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Intercept Pharmaceuticals, Inc.
Analyst Report: Intercept Pharmaceuticals, Inc.Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Rating
Fair Value
Economic Moat
2 years agoMorningstar

All

Investor's Business Daily
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.
Zacks
Does Intercept (ICPT) Have the Potential to Rally 52.08% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 52.1% in Intercept (ICPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Can Silver Spike Investment Corp. (SSIC) Climb 31.26% to Reach the Level Wall Street Analysts Expect?
  Zacks
- How Much Upside is Left in CS Disco (LAW)? Wall Street Analysts Think 43.32%
  Zacks
Zacks
Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA
Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.